niacinamide has been researched along with Carcinoma, Pancreatic Ductal in 6 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pharmacokinetic analysis revealed that oral dosing of t-CUPM resulted in higher blood levels than that of sorafenib throughout the complete time course (48 h)." | 1.43 | Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM. ( Hammock, BD; Hwang, SH; Li, H; Liao, J; Liu, JY; Wecksler, AT; Yang, GY; Yang, J; Yang, Y, 2016) |
| "Sorafenib is a multikinase inhibitor of the Ras/Raf/MEK/ERK pathway and of tumor angiogenesis." | 1.39 | Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. ( Awasthi, N; Hinz, S; Schwarz, MA; Schwarz, RE; Zhang, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Selvanesan, BC | 1 |
| Meena, K | 1 |
| Beck, A | 1 |
| Meheus, L | 1 |
| Lara, O | 1 |
| Rooman, I | 1 |
| Gravekamp, C | 1 |
| Awasthi, N | 1 |
| Zhang, C | 1 |
| Hinz, S | 1 |
| Schwarz, MA | 1 |
| Schwarz, RE | 1 |
| Stenzinger, A | 1 |
| Endris, V | 1 |
| Klauschen, F | 1 |
| Sinn, B | 1 |
| Lorenz, K | 1 |
| Warth, A | 1 |
| Goeppert, B | 1 |
| Ehemann, V | 1 |
| Muckenhuber, A | 1 |
| Kamphues, C | 1 |
| Bahra, M | 1 |
| Neuhaus, P | 1 |
| Weichert, W | 1 |
| Liao, J | 1 |
| Hwang, SH | 1 |
| Li, H | 1 |
| Yang, Y | 1 |
| Yang, J | 1 |
| Wecksler, AT | 1 |
| Liu, JY | 1 |
| Hammock, BD | 1 |
| Yang, GY | 1 |
| Plentz, RR | 1 |
| Manns, MP | 1 |
| Greten, TF | 1 |
| Wei, F | 1 |
| Liu, Y | 1 |
| Bellail, AC | 1 |
| Olson, JJ | 1 |
| Sun, SY | 1 |
| Lu, G | 1 |
| Ding, L | 1 |
| Yuan, C | 1 |
| Wang, G | 1 |
| Hao, C | 1 |
1 review available for niacinamide and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
5 other studies available for niacinamide and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Model | 2020 |
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Proce | 2013 |
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferat | 2013 |
Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzoates; Carcinoma, Pancreatic Ductal; Cell | 2016 |
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Pancreatic Ductal; Cel | 2012 |